International Journal of Environmental Research and Public Health
ISSN 1660-4601
www.mdpi.com/journal/ijerph

Article

Hematological and Biochemical Data Obtained in Rural Northern Uganda

Nirianne M. Q. Palacpac 1, Edward Ntege 2,3, Betty Balikagala 2,3, Adoke Yeka 2,4, Hiroki Shirai 5, Nahoko Suzuki 5,6, Christopher Nsereko 7,8, Bernard N. Kanoi 2,3, Takuya Okada 5, Thomas G. Egwang 2 and Toshihiro Horii 1,*

1 Department of Molecular Protozoology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan; E-Mail: nirian@biken.osaka-u.ac.jp
2 Med Biotech Laboratories, P.O. Box 9364, Kampala, Uganda; E-Mails: ehntege@gmail.com (E.N.); bettymawagali@gmail.com (B.B.); yadoke@yahoo.com (A.Y.); bnkanoi@gmail.com (B.N.K.); tgegwang@gmail.com (T.G.E.)
3 Proteo-Science Center, Ehime University, 3 Bunkyo-cho, Matsuyama, Ehime 790-8577, Japan
4 Makerere University School of Public Health, P.O. Box 7072, Kampala, Uganda
5 The Research Foundation for Microbial Diseases of Osaka University, 2-9-41 Yahata-cho, Kanonji, Kagawa 768-0061, Japan; E-Mails: hshirai@mail.biken.or.jp (H.S.); napokoko@gmail.com (N.S.); tkokada@mail.biken.or.jp (T.O.)
6 The London School of Economics and Political Science, Houghton Street, London WC2A 2AE, UK
7 Lira Medical Center, Lira, Uganda; E-Mail: chrisdoc23@yahoo.com
8 Muhimbili University of Health and Allied Sciences, United Nations Road, Dar es Salaam, P.O. Box 65001, Tanzania

* Author to whom correspondence should be addressed; E-Mail: horii@biken.osaka-u.ac.jp; Tel.: +81-6-6879-8280; Fax: +81-6-6879-8281.

Received: 26 February 2014; in revised form: 21 April 2014 / Accepted: 30 April 2014 / Published: 6 May 2014

Abstract: Reference intervals for common hematological and clinical chemistry parameters constitute an important basis for health care. Moreover, with increasing priority in drug and vaccine development for infectious diseases in Africa, the first priority is the safety evaluation and tolerability of the candidate interventions in healthy populations. To accurately assess health status and address adverse events, clinical reference intervals in the target population are necessary. We report on hematological and biochemical indices from healthy volunteers who participated in a clinical trial in Lira, northern Uganda.
Median and nonparametric 95% percentiles on five hematology and 15 biochemistry analytes are shown. Although most hematological analytes conformed to reported reference intervals and trends in Africa, literature review from different African countries highlight the need for a region-specific children reference interval that can be appropriate for the population.

Keywords: reference intervals; clinical trials; hematology; biochemistry; adult reference values; children reference values

1. Introduction

Reference intervals are used to describe the dispersion or fluctuation of analytes in healthy individuals; as indicators of good health or for accurate interpretation of physiological or pathological conditions in clinical and research environments. They are of particular importance in clinical trials especially in Africa [1], guiding the screening and enrollment of prospective participants as well as the safety assessment of investigational products. Phase I/II trials rely on enrollment and assessment of healthy participants for proper safety evaluation of interventions prior to phase III trials where safety and efficacy are evaluated on a larger scale. In April–May and September–October 2010, screening for enrollment in a phase Ib age de-escalation vaccine trial to assess the safety and immunogenicity of the BK-SE36 malaria vaccine was conducted at Lira Medical Centre (LMC), Lira, Uganda [2]. The trial assessed for eligibility 100 adults (>21 year-old) and 150 volunteers aged 6–20 years. Inclusion and exclusion criteria were based on reference values obtained from LMC as well as from a number of publications that address reference intervals in Africa [3–7]. From our experience, the reference values were not easily applicable to the phase 1b clinical trial, one of the reasons that contributed to a high screening to enrollment ratio. This resulted in logistical, personnel, as well as financial concerns. Reference intervals could also falsely exclude otherwise eligible volunteers making the process of trial recruitment and enrollment challenging. Likewise, inappropriate participant selection may bias trial results such that data become less generalizable to the healthy population being studied.

Prior to 2008, in most large-population based reference interval studies, the health status of participants were not assessed thoroughly and no additional medical or laboratory examinations were performed [3,4]. Majority of the reports also focused only on adults [3,4,8–10] and few included biochemistry reference values [5–7,11]. With publication of the International Federation of Clinical Chemistry (IFCC) and Clinical and Laboratory Standards Institute (CLSI) revised guidelines in 2008 [12], reference interval studies in Africa have increased [13–17] with some including children in their analyses [18,19]. These studies demonstrate differences in reference values compared to established US reference intervals [5,7,13,14,16,19,20].

Here, we present hematological and biochemical indices of healthy volunteers aged 6–32 years old who participated in the Phase Ib clinical trial. From the screening of healthy volunteers, we had the opportunity to collect and compare both hematological and biochemical data from these volunteers and re-assess previously reported reference intervals in Uganda as well as in Africa. Besides, the well-defined inclusion and exclusion criteria applied in the trial represent a data set from a northern
Uganda population that can typically participate in intervention trials and vaccine studies. The results also underscore the need for region-specific children reference intervals that can be more appropriate for the population.

2. Experimental Section

2.1. Study Population

In this study, only the screening visit data of volunteers who participated in the BK-SE36 Phase Ib clinical trial [2] was included in the analysis. The study took place at Lira Medical Center in Lira district, Northern Uganda. Lira district is approximately 1063 m above sea level and lies 347 km north of Kampala, the capital of Uganda. The district is predominantly agricultural, with the population comprising largely small landholder subsistence farmers: growing beans and cassava; owning chicken and goats [21]. The staple foods are mainly maize, cassava, sorghum and sweet potatoes. The area has a tropical climate with a temperature range of 17.4–30.3 °C and an average rainfall of 1478 mm/year [21].

Briefly, there were two stages of screening. Stage 1 was in 21–40 year-olds (n = 56) and Stage 2 was in 3 age cohorts (6–10, 11–15 and 16–20 years old). Screening for Stage 1 was conducted in April–May 2010 and for Stage 2 in September–October 2010. The trial was conducted in compliance with the study protocol, the International Conference on Harmonization’s Good Clinical Practice standards, the Declaration of Helsinki and Uganda regulatory requirements. Approvals for the protocol, subject information and informed consent forms were obtained from the ethical institutional review committees (IRC) of Osaka University (RIMD-IRC) (Japan), Research Foundation for Microbial Diseases of Osaka University (BIKEN-IRC) (Japan), Med Biotech Laboratories (MBL-IRC) (Uganda), and regulatory bodies Uganda National Council for Science and Technology (UNCST) and the Uganda National Drug Authority (NDA). Informed consent was obtained in English, Swahili or Luo (the language commonly spoken locally). Written consent was obtained from all enrolled subjects, in addition to individual assent from children aged eight and above. All participants were screened through a medical history questionnaire and complete physical examination. Females of child bearing age were tested for pregnancy. Selected participants were healthy, with no obvious symptoms/signs of either acute or chronic respiratory, cardiovascular, gastrointestinal, hepatic or renal disease; no history of blood donation/transfusion within one month and, for females, non-lactating. A detailed report of the study population recruitment, enrollment, inclusion/exclusion criteria, and blood sampling has been published [2].

Whole blood samples were collected from fasting subjects via venipuncture with a Vacutainer system (Becton Dickinson Biosciences, Franklin Lakes, NJ, USA), with all blood drawn in the morning (7:00–12:00 am) and hematological and biochemistry tests performed within the day. The samples were also checked for malaria parasites. Blood sampling and processing were done according to standard operating procedures by trained laboratory staff (EDTA treated tubes for hematology and untreated tubes for biochemistry tests). Hematological indices were measured by Sysmex KX-21N (Sysmex Corporation, Kobe, Japan); and biochemical indices by Cobas C111 (Roche Diagnostics, Mannheim, Germany) per manufacturer’s instructions. Daily quality control was performed on the equipment and all laboratory procedures adhered to Good Clinical Laboratory Practices. Calibrators
and controls were obtained from the instrument manufacturer. For hematology tests, daily running of the 3-part Differential Whole Blood Para® Check (Para® Check Low, Para® Check Normal and Para® Check High) controls ensured calibration and quality control limits for each analyte. For Cobas C111, we used normal (PreciNorm U) and abnormal (PreciPath U) control sera from Roche Diagnostics. In addition, the laboratory was under an external quality assurance program with the South African National Accreditation System. Assessments included white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin (Hb), hematocrit (Hct), platelet count, alkaline phosphatase (AL-P), alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl-transferase (γ-GTP), amylase, albumin, total protein, total bilirubin, cholesterol, glucose, creatinine, urea nitrogen (BUN), uric acid, potassium and sodium.

2.2. Statistical Methods

Data were pooled, analyzed untransformed and are shown as mean, median, maximum-minimum values, and 95% reference intervals according to CLSI C28-A3 guideline [12]. Of the measured analyte, 70% did not conform to a Gaussian distribution according to the D’Agostino and Pearson and Shapiro-Wilk tests for normality. Outlier exclusion was the recommended Dixon-Reed’s outlier method. Non-parametric percentiles and 90% CIs were determined. Possible partitioning to two broad age groups: 6–15 years-old and 16–32 years-old were done using the robust method with possible outliers detected by visual inspection of distributions and Tukey’s criterion. Analytes that have significant age differences based on the non-parametric Mann-Whitney U test are shown in Table 3. Statistical analyses were performed using MedCalc for Windows, version 13.1.1.0 (MedCalc Software, Ostend, Belgium) and GraphPad Prism 6 (GraphPad Software; La Jolla, CA, USA).

3. Results and Discussion

3.1. Baseline Characteristics of the Study Population

From April–May and September–October 2010 (two sampling periods), we enrolled a total of 140 healthy individuals [2]. We report on the health status of these individuals based on hematological and biochemical data obtained. The final analysis cohort pooled participants from age 6–32 years-old. Table 1 shows the general characteristics of the study population. In adults (21–32 years), mean age and body mass index (BMI) were similar across gender. Lower mean diastolic and systolic blood pressure (BP) but higher mean pulse rate was obtained from female than male volunteers. In younger cohorts, as expected weight, height and BMI increased with age. Diastolic and systolic BP were similar across age groups, although pulse rate of 6–10 years and 11–15 year-old cohorts were significantly higher than 16–20 years cohort. In the 16–20 year-old cohort, male-to-female ratio was 1:1. However, there was a preponderance of females in the 6–10 year-old cohort (representing 54% against 46%) and in 11–15 year-old cohort (82% vs. 18% males).
3.2. Hematological Analysis

The mean, standard deviation, median, minimum/maximum values and 95% reference intervals for hematology analytes are given in Table 2. Volunteers had low WBC and platelet counts. Ranges for RBC count, hematocrit and hemoglobin values were generally broad when compared to Western reference intervals obtained from Pathology Associates Medical Laboratories [22]. The low hemoglobin; hematocrit; white blood cell, erythrocyte and platelet counts in Africans compared to northern European population or whites have been shown to be related to ethnicity and/or genetic factors [23–25]. Significant age differences for red cell indices were obtained when reference intervals were partitioned to two broad age groups (6–15 and 16–32 years-old). When computed by the robust method as recommended by CLSI C28-A3 guidelines, age differences were evident in the upper values for RBC count \( (p = 0.009) \), hemoglobin \( (p < 0.0001) \) and hematocrit \( (p < 0.0001) \) in 16–32 year-old compared to 6–15 year-old (Table 3). The increase in hemoglobin, hematocrit and erythrocyte counts; as well as the decrease in platelet counts according to age has been reported [4,19,20]. Values were within the 2.5 and 97.5 percentiles obtained from Uganda and other African countries with an altitude below 2000 m (Table 4). Higher hemoglobin and hematocrit values were reported for Ethiopia (at >2300 m above sea level) and lower hemoglobin and hematocrit were noted for Ghana (at 60–150 m above sea level).

3.3. Biochemical Analysis

The mean, standard deviation, median, minimum/maximum values and 95% reference intervals for biochemistry values are summarized in Table 2. Most biochemical analytes were within reference intervals reported for the Western population [22,26] with the exception of ALT, γ-GTP, creatinine, protein, bilirubin, potassium and sodium. The lower limit for ALT; higher limits for protein, bilirubin and sodium have been recorded in the Ugandan population [7]. We also observed significant age differences in reference intervals for the following indices: AL-P \( (p < 0.0001) \), AST \( (p < 0.0001) \), amylase \( (p = 0.02) \), glucose \( (p < 0.0001) \), creatinine \( (p < 0.0001) \), urea nitrogen (BUN, \( p = 0.002 \)), uric acid \( (p < 0.0001) \), potassium \( (p = 0.002) \) and sodium \( (p < 0.0001) \) (Table 3). Using the robust method, in adults, the reference ranges obtained fell at the lower end of the current reference intervals reported for Uganda and other African countries (Table 5). In adolescents and young children there are, at present, only a handful of studies available (Table 6).
Table 1. Study population characteristics in different age groups (n = 140).

| Analyte | 6–10 Years old (n = 28) | 11–15 Years old (n = 28) | 16–20 Years old (n = 28) | Male >20 Years old (n = 28) | Female >20 Years old (n = 28) |
|---------|------------------------|--------------------------|---------------------------|-----------------------------|-------------------------------|
|         | Mean | SD | Min/Max | Mean | SD | Min/Max | Mean | SD | Min/Max | Mean | SD | Min/Max | Mean | SD | Min/Max |
| Age *   | 8.11 | 1.52 | 6/10 | 12.68 | 1.25 | 11/15 | 17.96 | 0.99 | 16/20 | 22.61 | 1.26 | 21/25 | 22.14 | 2.14 | 21/32 |
| BMI     | 16.06 | 1.54 | 13.9/19.8 | 18.25 | 2.38 | 15.4/24.2 | 20.60 | 1.90 | 18.1/25 | 21.35 | 1.82 | 18/25 | 22.14 | 2.56 | 18.4/28 |
| Weight  | 28.35 | 5.61 | 17/42 | 43.18 | 8.00 | 33.5/63 | 57.79 | 4.27 | 49/67 | 62.78 | 6.36 | 50.1/75.3 | 59.74 | 7.53 | 48.5/74.5 |
| Height  | 132.2 | 9.99 | 110.5/153 | 153.5 | 7.49 | 140/169.7 | 167.8 | 7.13 | 157/182.2 | 171.4 | 5.90 | 161.5/184.3 | 164.2 | 5.87 | 153.7/183 |
| DBP     | 69.61 | 4.49 | 60/78 | 71.29 | 6.92 | 60/82 | 73.43 | 6.55 | 60/86 | 73.54 | 7.10 | 58/87 | 72.64 | 7.37 | 57/87 |
| SBP     | 115.6 | 8.19 | 96/126 | 119.0 | 8.12 | 105/129 | 118.9 | 8.05 | 102/131 | 120.1 | 13.46 | 100/142 | 108.8 | 11.07 | 89/135 |
| Pulse rate | 82.82 | 10.23 | 66/107 | 78.79 | 10.57 | 60/97 | 69.64 | 8.73 | 55/90 | 67.25 | 6.26 | 55/79 | 70.25 | 8.96 | 55/92 |

* Age (year); BMI (kg/m²); weight (kg); height (cm); DBP (diastolic blood pressure; mmHg); SBP (systolic blood pressure, mmHg); pulse rate (bpm).
Table 2. Means, median and 95% percentile reference ranges for hematology and biochemistry analytes in 6–32 year old.

| Analyte   | n  | Mean  | SD   | Median | Min/Max | Lower Limit | 95% Reference Interval | 90% CI | Upper Limit | 90% CI |
|-----------|----|-------|------|--------|---------|-------------|------------------------|-------|-------------|-------|
| WBC §     | 140| 5.66  | 1.47 | 5.4    | 3.3/10.8| 3.6          | 3.3–3.8                | 9.99  | 8.3–10.8    |
| RBC       | 140| 5.06  | 0.55 | 4.98   | 3.9/6.6 | 4.1          | 3.9–4.2                | 6.28  | 6.11–6.58   |
| Hb        | 140| 13.75 | 1.64 | 13.5   | 10/18.2 | 10.55        | 10–11.6                | 17.5  | 16.6–18.2   |
| Hct       | 140| 41.11 | 4.35 | 40.8   | 31.4/51.5| 33.3         | 31.4–35.5              | 50.35 | 49.4–51.5   |
| Platelet  | 140| 228.5 | 63.23| 222    | 115/473 | 118.53       | 115–135                | 392.7 | 337–473     |
| AL-P      | 138| 151.8 | 106.9| 95.8   | 42.8/456.2| 44.1         | 42.8–48.2              | 394.9 | 355.8–456.2|
| ALT       | 140| 15.99 | 5.61 | 14.95  | 6.5/43.5 | 8.9          | 6.5–9.7                | 35.31 | 24.4–43.5   |
| AST       | 139| 21.53 | 4.37 | 21.3   | 13.4/36.5| 14.3         | 13.4–15.5              | 33.9  | 28.7–36.5   |
| γ-GTP     | 139| 13.09 | 6.52 | 11.6   | 3.5/45.6 | 4.05         | 3.5–5.5                | 29.85 | 26–45.6     |
| Amylase   | 140| 27.21 | 8.95 | 25.65  | 12.7/74.9| 15.17        | 12.7–16.3              | 52.75 | 43.4–74.9   |
| Albumin   | 140| 4.6   | 0.26 | 4.61   | 3.8/5.3 | 4.08         | 3.8–4.2                | 5.04  | 4.99–5.3    |
| Protein   | 140| 7.6   | 0.59 | 7.5    | 5.7/9.5 | 6.25         | 5.7–6.7                | 8.6   | 8.5–9.5     |
| Bilirubin | 140| 0.54  | 0.38 | 0.4    | 0.1/1.9 | 0.1          | 0.1–0.1                | 1.7   | 1.3–1.9     |
| Cholesterol| 140| 128.7 | 25.1 | 128.1  | 71.6/188.9| 85.55        | 71.6–91.8              | 174.15| 167.5–188.9|
| Glucose   | 140| 84.7  | 10.23| 82.78  | 67.6/118.9| 69.5         | 67.6–71.8              | 114.6 | 103.9–118.9|
| Creatinine| 140| 0.59  | 0.15 | 0.6    | 0.4/1.0 | 0.4          | 0.4–0.4                | 0.95  | 0.9–1.0     |
| BUN       | 140| 14.94 | 4.55 | 14.16  | 2.84/29.68| 8.29         | 2.84–9.14              | 24.9  | 23.2–29.68  |
| Uric acid | 140| 3.85  | 0.83 | 3.8    | 2.1/6.9 | 2.4          | 2.1–2.6                | 5.59  | 5.3–6.9     |
| Potassium | 140| 4.24  | 0.39 | 4.24   | 3.4/5.42 | 3.57         | 3.41–3.64              | 5.27  | 4.9–5.42    |
| Sodium    | 140| 139.6 | 3.2  | 139.15 | 135.3/149.4| 135.5        | 135.3–135.8            | 148.5 | 145.8–149.4|

§ WBC (leukocyte count, ×10⁹/L); RBC (erythrocyte count, ×10¹²/L); Hb (hemoglobin, g/dL); Hct (hematocrit, %); Platelet count (×10⁹/L); AL-P (alkaline phosphatase, U/L); ALT (alanine aminotransferase, U/L); AST (aspartate aminotransferase, U/L); γ-GTP (γ-glutamyl transpeptidase, U/L); Amylase (serum amylase, U/L); Albumin (g/dL); Protein (total protein, g/dL); Bilirubin (total bilirubin, mg/dL); Cholesterol (total cholesterol, mg/dL); Glucose (mg/dL); Creatinine (mg/dL); BUN (urea nitrogen, mg/dL); Uric acid (mg/dL); Potassium (mmol/L); Sodium (mmol/L); SD = standard deviation; CI = confidence interval.
Table 3. 95% Reference interval for hematology and biochemistry analytes by age group *

| Analyte | 6–15 Years old | 16–32 Years old |
|---------|----------------|-----------------|
|         | n | Lower Limit | 90% CI | Upper Limit | 90% CI | n | Lower Limit | 90% CI | Upper Limit | 90% CI |
| **Hematology** | | | | | | | | | | |
| RBC § | 56 | 4.1 | 3.9–4.2 | 5.7 | 5.55–5.84 | 84 | 3.9 | 3.7–4.1 | 6.4 | 6.16–6.55 |
| Hb | 56 | 11.2 | 10.9–11.5 | 14.5 | 14.2–14.8 | 84 | 10.9 | 10.3–11.4 | 17.9 | 17.3–18.4 |
| Hct | 55 | 34.3 | 33.66–35 | 42.8 | 41.9–43.6 | 84 | 33.7 | 32.5–35.2 | 52.1 | 50.8–53.3 |
| **Biochemistry** | | | | | | | | | | |
| AL-P | 53 | 111.1 | 82.8–140.8 | 419.7 | 385.1–450.1 | 78 | 31.9 | 26.7–37.4 | 108.4 | 100.5–114.5 |
| AST | 55 | 16.14 | 14.96–17.5 | 29.9 | 28.7–31.1 | 80 | 12.99 | 11.99–14.1 | 26.11 | 25–27.15 |
| Amylase | 55 | 12.42 | 10.2–15.1 | 36.3 | 34.16–38.6 | 76 | 14.43 | 12.6–16.4 | 37.3 | 35–39.3 |
| Glucose | 54 | 66.4 | 62.7–70.65 | 109.3 | 103.9–114 | 80 | 67.2 | 65.4–69.3 | 91.3 | 89.1–93.5 |
| Creatinine | 55 | 0.31 | NC | 0.61 | NC | 84 | 0.43 | NC | 0.92 | NC |
| BUN | 56 | 5.14 | 3.7–6.6 | 21.29 | 19.4–22.8 | 83 | 6.05 | 4.69–7.4 | 24.4 | 22.5–25.9 |
| Uric acid | 56 | 2 | 1.78–2.25 | 4.88 | 4.58–5.18 | 83 | 2.5 | 2.28–2.77 | 5.59 | 5.34–5.82 |
| Potassium | 52 | 3.46 | 3.34–3.57 | 4.65 | 4.54–4.74 | 84 | 3.58 | 3.47–3.69 | 5.02 | 4.91–5.12 |
| Sodium | 56 | 134.2 | 133.5–134.8 | 141 | 140.2–141.7 | 84 | 133.87 | 133–134.8 | 147.4 | 146.2–148.54 |

* Calculated by the robust method recommended by CLSI C28-A3 guideline. NC, not calculated (not possible to calculate) for the subgroup. § RBC (erythrocyte count, ×10¹²/L); Hb (hemoglobin, g/dL); Hct (hematocrit, %); AL-P (alkaline phosphatase, U/L); AST (aspartate aminotransferase, U/L); Amylase (serum amylase, U/L); Glucose (mg/dL); Creatinine (mg/dL); BUN (urea nitrogen, mg/dL); Uric acid (mg/dL); Potassium (mmol/L); Sodium (mmol/L).
Table 4. Comparison of hematology ranges with other studies in Africa: 16–32 years-old.

| Analyte | This study* (16–32 years old) | Kenya, Uganda, Zambia, Rwanda † (18–60 years old) | Uganda ‡ (18–34 years old) | Western Kenya † (18–55 years old) | Kericho-Kenya † (18–55 years old) | Tanzania § (19–48 years old) | Ethiopia † (15–45 years old) | Central Africa † (17–58 years old) | Togo † (17–58 years old) | Ghana † (18–59 years old) | South Africa † (18–55 years old) |
|---------|-------------------------------|-----------------------------------------------|----------------------------|-----------------------------------|----------------------------------|-------------------------------|-------------------------------|-----------------------------------|-------------------|----------------------|-----------------------------|
| RBC ‡   | 3.9–6.4                       | 3.8–6.2 †                                   | 3.5–6.1 †                  | 4.3–6.5 †                        | 4–6.2 †                         | 4.01–6.12 †                  | 4.3–5.9 †                   | 3.7–5.2 †                         | 4.50–6.10         | 3.1–6.4 †             | 3.39–5.83 †               |
| Hb      | 10.9–17.9                     | 10.5–17.5 †                                 | 10.8–17.1 †                | 11.4–16.9 †                      | 8.0–14.2 †                     | 6.7–11.1 †                   | 11.7–17.2 †                 | 13.9–18.3 †                       | 12.3–17.3         | 10–18.4 †             | 13.4–17.5 †               |
| Hct     | 33.7–52.1                     | 31.6–51.7 †                                 | 31.2–49.5 †                | 32.6–51.5 †                      | 23.2–44.3 †                    | 30–50 †                      | 36.5–52.7 †                 | 41.6–55.1 †                        | 39–52             | 28–54 †              | 39–51 †                   |

§ RBC (erythrocyte count, ×10¹²/L); Hb (hemoglobin, g/dL); Hct (hematocrit, %). † Karita et al., 2009 [13] and IAVI, 2008 [27]; ‡ Eller et al., 2008 [7]; † Zeh et al., 2011 [19]; † Kibaya et al., 2008 [6]; † Saathoff et al., 2008 [5]; † Tsegaye et al., 1999 [9]; † Menard et al., 2003 [10]; † Kueviakoe et al., 2011 [15]; † Dosoo et al., 2012 [16]; † Lawrie et al., 2009 [14]. Shown are 95% reference intervals. * Calculated by the robust method recommended by CLSI C28-A3 guideline. † Indicates analytes with significant gender differences. If two values are shown, only separate male and female reference intervals, respectively were reported.
Table 5. Comparison of biochemistry ranges with other studies in Africa: 16–32 years-old.

| Analyte       | This study (21–32 years old) | Kenya, Uganda, Zambia, Rwanda 1 (18–60 years old) | Uganda 2 (18–56 years old) | Western Kenya 3 (18–34 years old) | Kericho-Kenya 4 (18–55 years old) | Tanzania 5 (19–48 years old) | Ghana 6 (18–59 years old) |
|---------------|------------------------------|-----------------------------------------------|----------------------------|-----------------------------------|---------------------------------|------------------------------|--------------------------|
| **Enzymes**   |                              |                                               |                            |                                   |                                 |                              |                          |
| AL-P (U/L)    | § 31.9–108.4                 | 48–164                                       | 44–151                     | 45.6–158.4                        | 585                             | 85–241 †                    |                          |
| n             | 78                           | 2103                                         | 433                        | 236                               | 595                             |                              |                          |
| AST (U/L)     | 12.99–26.11                  | 14–60                                        | 12.3–34.8 †                | 13.8–50.4                         | 13.8–42.3 †                     | 14.3–48.1 †                 | 14–51 †                  |
| n             | 80                           | 2103                                         | 845                        | 293                               | 1533                            | 269                         | 588                      |
| Amylase (U/L) | 14.43–37.3                   | 35–159                                       | 45.6–173.6                 | 38.3–163.0 †                      | 42.8–164.4                      | 32–139 †                    |                          |
| n             | 76                           | 2103                                         | 433                        | 1205                              | 270                             | 621                         |                          |
| **Metabolism**|                              |                                               |                            |                                   |                                 |                              |                          |
| Glucose (mg/dL) | 67.2–91.3                    |                                              |                            | 37.84–118.92                      | 55.8–102.7                      | 52.61–94.23                 | 64.87–115.32             |
| n             | 80                           | 293                                          |                            | 1541                              | 262                             | 622                         |                          |
| **Kidney function** |                          |                                               |                            |                                   |                                 |                              |                          |
| Creatinine (mg/dL) | 0.43–0.92                    | 0.53–1.23                                   | 0.5–1.2 †                   | 0.57–1.28                         | 0.62–1.15                       | 0.47–1.02 †                 | 0.55–1.33 †              |
| n             | 84                           | 2103                                         | 851                        | 293                               | 1540                            | 270                         | 615                      |
| BUN (mg/dL)   | 6.05–24.4                    | 4.6–15.5 †                                   | 3.36–14.29                 | 3.92–12.89 †                      | 4.29–13.89 †                    | 2.52–15.97 †                |                          |
| n             | 83                           | 848                                          | 293                        | 1541                              | 265                             | 622                         |                          |
| Uric acid (mg/dL) | 2.5–5.59                    | 3.3–7.8 †                                   | 2.76–7.5 †                 | 1.52–6.7 †                        |                                  |                              |                          |
| n             | 83                           | 729                                          |                            | 270                               | 620                             |                              |                          |
| **Electrolytes** |                              |                                               |                            |                                   |                                 |                              |                          |
| Potassium (mmol/L) | 3.58–5.02                    | 3.4–4.8                                      | 3.9–5.8 †                   | 3.83–5.52 †                       | 3.6–5.2 †                      |                              |                          |
| n             | 84                           | 849                                          | 1535                       | 269                               | 583                             |                              |                          |
| Sodium (mmol/L) | 133.9–147.4                 | 135.3–147.6 †                               | 141.4–152.5               | 133.6–142.5 †                     | 135–150                         |                              |                          |
| n             | 84                           | 849                                          | 1541                       | 257                               | 541                             |                              |                          |

† AL-P, alkaline phosphatase; AST, aspartate aminotransferase; BUN, urea nitrogen. 1 Karita, et al., 2009 [13] and IAVI, 2008 [27]; 2 Eller, et al., 2008 [7]; 3 Zeh, et al., 2011 [19]; 4 Kibaya, et al., 2008 [6]; 5 Saathoff, et al., 2008 [5]; 6 Dosoo, et al., 2012 [16]. Shown are 95% reference intervals. When a value is preceded by †, analyte was reported to have significant gender differences ($p < 0.05$).
Table 6. Comparison of hematology and biochemistry ranges with other studies in Africa: 6–15 years-old.

| Analyte          | This study * | Uganda † (90% intervals) | Western Kenya ‡ |
|------------------|--------------|--------------------------|-----------------|
|                  |              |                          |                 |
| **Hematology**   |              |                          |                 |
| RBC (×10¹²/L) §  | 4.08–5.7     | 3.8–5.4 †                | (4.1–5.8) (3.3–5.4) † |
| n                | 56           | 731                      | 133             |
| Hb (g/dL)        | 11.18–14.55  | 10.0–13.7 †              | (10.6–15.6) (8.1–14.2) † |
| n                | 56           | 731                      | 133             |
| Hct (%)          | 34.3–42.8    | 29.2–39.4 †              | (29.3–48.1) (24.8–43.1) † |
| n                | 55           | 731                      | 133             |
| **Biochemistry** |              |                          |                 |
| AL-P (U/L) ‡     | 111.1–419.7  |                         |                 |
| n                | 53           |                          |                 |
| AST (U/L)        | 16.14–29.9   | (17.0–59.2)              | (12.0–43.1) †   |
| n                | 55           | 293                      |                 |
| Amylase (U/L)    | 12.42–36.3   |                         |                 |
| n                | 55           |                          |                 |
| **Metabolism**   |              |                          |                 |
| Glucose (mg/dL)  | 66.4–109.3   | (37.84–118.92)           |                 |
| n                | 54           |                          | 293             |
| **Kidney function** |          |                          |                 |
| Creatinine (mg/dL)| 0.31–0.61   |                         |                 |
| n                | 55           |                          |                 |
| BUN (mg/dL)      | 5.14–21.29   | (3.36–14.29)             |                 |
| n                | 56           |                          | 293             |
| Uric acid (mg/dL)| 2–4.88      |                         |                 |
| n                | 56           |                          |                 |
| **Electrolytes** |              |                          |                 |
| Potassium (mmol/L)| 3.46–4.65   |                         |                 |
| n                | 52           |                          |                 |
| Sodium (mmol/L)  | 134.2–141    |                         |                 |
| n                | 56           |                          |                 |

† RBC, erythrocyte count; Hb, hemoglobin; Hct, hematocrit; AL-P, alkaline phosphatase; AST, aspartate aminotransferase; BUN, urea nitrogen. † Except for Lugada et al., 2004 [4], shown are 95% reference intervals. When two values are provided, these correspond to male and female ranges, respectively. † Indicates analytes with significant age and gender differences (p < 0.05); age range listed is 6–12 years for † Lugada et al., 2004 [4]; 13–17 years for † Zeh et al., 2011 [19].
4. Conclusions

The opportunity to re-assess currently used reference intervals in northern Uganda presented itself when we conducted a phase 1b trial in Lira, Uganda. Reference intervals serve as a valuable guide for interpretation of laboratory results. Hematology and biochemistry analytes are influenced by a number of factors such as sex, age, ethnic origin, environment (including geographical location, access to health care), constitutional abnormalities (thalassemia, sickle cell disease), pathologic conditions (malaria, HIV and HBV viral infections); and to some extent demographic changes and technological advancement in analyte measurements [4–7,13–20,23,27,28].

The revised international guidelines from CLSI recommend that if it is not possible to establish detailed reference studies from at least 120 individuals, validation using as few as 20 samples could be helpful together with comparison using published reference intervals and performing posteriori methods [29,30]. We, thus, examined and compared the variability of hematological and biochemical analytes obtained during participant screening for trial enrollment. The analytes were commonly used for clinical assessments to guide inclusion/exclusion into the trial and for adverse event evaluation.

The studied population is heterogeneous with regards to age and gender. However, overall, the upper and lower limits of the reference intervals obtained in this study were almost the same as the limits reported in previous adult hematologic reference intervals (Table 4). Trends of age-specific differences in some parameters were also evident although this needs further verification in larger cohorts (Table 6). At present there are few reports available for adolescents and younger age groups, especially on biochemistry analytes in Africa [11,19,31,32].

Whether gender or age would alter the reference intervals obtained in the present study is for further studies. The screening activity did not screen out all medical conditions such as hepatitis B, HIV or other parasitic infections except for malaria. We have no information on social habits (tobacco use, diet, alcohol consumption, exercise, etc.) as these were not obtained during enrollment of the volunteers (e.g., factors such as smoking has been reported to affect hemoglobin values [14]). We did, however, have a well-defined trial inclusion and exclusion criteria, and all subject were evaluated for both hematological and biochemical indices. Volunteers were encouraged to come for screening to the study clinic after fasting for at least 8 h. Breakfast was given to all participants afterwards and this assisted in a high level of compliance with this request, although in some cases fasting was interpreted as an instruction not to eat or drink and, thus, some volunteers were mildly dehydrated during blood sample collection. Nevertheless, the study provides preliminary data needed to facilitate health care and research trials in a population in which reference interval generation has not yet been done. Participants in the study also represent volunteers that would participate in clinical trials. Importantly, we also highlight the need for local data especially in younger age groups as their participation in clinical trial is solicited.

Acknowledgments

This article is based on the screening activities of Phase 1b clinical trial. The funding from the trial sponsor, Research Foundation for Microbial Diseases of Osaka University (BIKEN) is hereby acknowledged. The findings and conclusions in this manuscript are those of the authors and do not
necessarily represent the views of BIKEN. Authors also acknowledge the support of ‘Funds for integrated promotion of social system reform and research and development’, MEXT under the project: Development and Sustainability of Malaria Vaccine Clinical Research Center (38201103-01).

Author Contributions

Nirianne M. Q. Palacpac conceived and conducted the study, analyzed the data and prepared the draft of the manuscript; Edward Ntege and Betty Balikagala conducted the study, analyzed the data and prepared the draft of the manuscript; Adoke Yeka supervised and conducted the study; Hiroki Shirai conceived and supervised the study; Nahoko Suzuki conceived and conducted the study, and analyzed the data; Christopher Nsereko and Bernard N. Kanoi conducted the study; Takuya Okada conducted the study and analyzed the data; Thomas G. Egwang conceived and supervised the study; Toshihiro Horii conceived and supervised the study, and gave final approval of the manuscript to be submitted for publication.

Conflicts of Interest

Authors, except Toshihiro Horii, are current or previous employees of BIKEN; or received remuneration to conduct the clinical trial.

References

1. Mwangoka, G.; Ogutu, B.; Msambichaka, B.; Mzee, T.; Salim, N.; Kafuruki, S.; Mpina, M.; Shekalaghe, S.; Tanner, M.; Abdulla, S. Experience and challenges from clinical trials with malaria vaccines in Africa. Malar. J. 2013, 12, 86:1–86:9, doi:10.1186/1475-2875-12-86.
2. Palacpac, N.M.; Ntege, E.; Yeka, A.; Balikagala, B.; Suzuki, N.; Shirai, H.; Yagi, M.; Ito, K.; Fukushima, W.; Hirota, Y.; et al. Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine BK-SE36. PLoS One 2013, 8, e64073:1–e64073:14, doi:10.1371/journal.pone.0064073.
3. Tugume, S.B.; Piwowar, E.M.; Lutalo, T.; Muyenyi, P.N.; Grant, R.M.; Mangeni, F.W.; Pattishall, K.; Katongole-Mbidde, E. Hematological reference ranges among healthy Ugandans. Clin. Diagn. Lab. Immunol. 2004, 11, 29–34.
4. Lugada, E.S.; Mermin, J.; Kaharuza, F.; Ulvestad, E.; Were, W.; Langeland, N.; Asjo, B.; Malamba, S.; Downing, R. Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin. Diagn. Lab. Immunol. 2004, 11, 29–34.
5. Saathoff, E.; Schneider, P.; Kleinfeldt, V.; Geis, S.; Haule, D.; Maboko, L.; Samky, E.; de Souza, M.; Robb, M.; Hoelscher, M. Laboratory reference values for healthy adults from southern Tanzania. Trop. Med. Int. Health 2008, 13, 612–625.
6. Kibaya, R.S.; Bautista, C.T.; Sawe, F.K.; Shaffer, D.N.; Sateren, W.B.; Scott, P.T.; Michael, N.L.; Robb, M.L.; Birx, D.L.; de Souza, M.S. Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya. PLoS One 2008, 3, e3327:1–e3327:7, doi:10.1371/journal.pone.0003327.
7. Eller, L.A.; Eller, M.A.; Ouma, B.; Kataaha, P.; Kyabaggu, D.; Tumusiime, R.; Wandege, J.; Sanya, R.; Sateren, W.B.; Wabwire-Mangen, F.; et al. Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials. *PLoS One* 2008, 3, e3919:1–e3919:6, doi:10.1371/journal.pone.0003919.

8. Tikly, M.; Blumsohn, D.; Solomons, H.D.; Govender, Y.; Atkinson, P.M. Normal haematological reference values in the adult black population of the Witwatersrand. *S. Afr. Med. J.* 1987, 72, 135–136.

9. Tsegaye, A.; Messele, T.; Tilahun, T.; Hailu, E.; Sahl, T.; Doorly, R.; Fontanet, A.L.; Rinke de Wit, T.F. Immunohematological reference ranges for adult Ethiopians. *Clin. Diagn. Lab. Immunol.* 1999, 6, 410–414.

10. Menard, D.; Mandeng, M.J.; Tothy, M.B.; Kelembho, E.K.; Gresenguet, G.; Talarmin, A. Immunohematological reference ranges for adults from the Central African Republic. *Clin. Diagn. Lab. Immunol.* 2003, 10, 443–445.

11. Quintó, L.; Aponte, J.J.; Sacarlal, J.; Espasa, M.; Aide, P.; Mandomando, I.; Guinovart, C.; Macete, E.; Navia, M.M.; Thompson, R.; Menéndez, C.; Alonso, P.L. Haematological and biochemical indices in young African children: In search of reference intervals. *Trop. Med. Int. Health.* 2006, 11, 1741–1748.

12. CLSI. *Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline*, 3rd ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2008.

13. Karita, E.; Ketter, N.; Price, M.A.; Kayitenkore, K.; Kaleebu, P.; Nanvubya, A.; Anzala, O.; Jaoko, W.; Mutua, G.; Ruzagira, E.; et al. CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. *PLoS One* 2009, 4, e4401:1–e4401:14, doi:10.1371/journal.pone.0004401.

14. Lawrie, D.; Coetzee, L.M.; Becker, P.; Mahlangu, J.; Stevens, W.; Glencross, D.K. Local reference ranges for full blood count and CD4 lymphocyte count testing. *S. Afr. Med. J.* 2009, 99, 243–248.

15. Kueviakoe, I.M.; Segbena, A.Y.; Jouault, H.; Vovor, A.; Imbert, M. Hematological reference values for healthy adults in Togo. *I.S.R.N. Hematol.* 2011, 2011, 736062:1–736062:5, doi:10.5402/2011/736062.

16. Dosoo, D.K.; Kayan, K.; Adu-Gyasi, D.; Kwara, E.; Ocra, J.; Osei-Kwakye, K.; Mahama, E.; Amenga-Etego, S.; Bilson, P.; Asante, K.P.; et al. Haematological and biochemical reference values for healthy adults in the middle belt of Ghana. *PLoS One* 2012, 7, e36308:1–e36308:9, doi:10.1371/journal.pone.0036308.

17. Isa, A.H.; Hassan, A.; Garba, Y.; Ijei, I.P. Reference ranges of some haematological parameters in healthy northern Nigerian adults. *Jos. J. Med.* 2012, 6, 16–18. Available online: http://www.ajol.info/index.php/jjm/article/viewFile/84360/74361 (accessed on 18 February 2014).

18. Buchanan, A.M.; Muro, F.J.; Gratz, J.; Crump, J.A.; Musyoka, A.M.; Sichangi, M.W.; Morrissey, A.B.; M’rimberia, J.K.; Njau, B.N.; Msuya, L.J.; et al. Establishment of haematological and immunological reference values for healthy Tanzanian children in Kilimanjaro Region. *Trop. Med. Int. Health.* 2010, 15, 1011–1021.
19. Zeh, C.; Amornkul, P.N.; Inzaule, S.; Ondoa, P.; Oyaro, B.; Mwaengo, D.M.; Vandenhoudt, H.; Gichangi, A.; Williamson, J.; Thomas, T.; et al. Population-based biochemistry, immunologic and hematological reference values for adolescents and young adults in a rural population in Western Kenya. *PLoS One* 2011, 6, e21040:1–e21040:10, doi:10.1371/journal.pone.0021040.

20. Adetifa, I.M.; Hill, P.C.; Jeffries, D.J.; Jackson-Sillah, D.; Ibanga, H.B.; Bah, G.; Donkor, S.; Corrah, T.; Adegbola, R.A. Haematological values from a Gambian cohort—Possible reference range for a West African population. *Int. J. Lab. Hematol.* 2009, 31, 615–622.

21. Uganda Bureau of Statistics. 2012 Statistical Abstract. Available online http://www.ubos.org/onlinefiles/uploads/ubos/pdf%20documents/2012StatisticalAbstract.pdf. (accessed on 18 February 2014).

22. PAML and Testing Partners Update Reference Ranges across the Network. Available online: http://www.paml.com/Files/PAML/Reports/Reference%20Ranges_PAML_RR_0001.pdf (accessed on 18 February 2014).

23. Bain, B.J. Ethnic and sex differences in the total and differential white cell count and platelet count. *J. Clin. Pathol.* 1996, 49, 664–666.

24. Beutler, E.; West, C. Hematologic differences between African-Americans and whites: The roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume. *Blood* 2005, 106, 740–745.

25. Robins, E.B.; Blum, S. Hematologic reference values for African American children and adolescents. *Am. J. Hematol.* 2007, 82, 611–614.

26. Andropoulos, D.B. Appendix B: Pediatric Normal Laboratory Values. In *Gregory’s Pediatric Anesthesia*, 5th ed.; Gregory, G.A., Andropoulos, D.B., Eds.; Wiley-Blackwell: Oxford, UK, 2012.

27. International AIDS Vaccine Initiative (IAVI). *Establishing Clinical Laboratory Reference Intervals in Africa: A Cross-Sectional, Observational Study in Healthy Adults at Multiple African Research Centers*; IAVI: New York, NY, USA, 2008. Available online: http://www.iavi.org/Information-Center/Publications/Documents/IAVI_Establishing_Clinical_Lab_Reference_Intervals_in_Africa_2008_ENG.pdf (accessed on 19 February 2014).

28. Ngowi, B.J.; Mfinanga, S.G.; Bruun, J.N.; Morkve, O. Immunohaematological reference values in human immunodeficiency virus-negative adolescent and adults in rural northern Tanzania. *BMC Infect. Dis.* 2009, 9, 1:1–1:7, doi:10.1186/1471-2334-9-1.

29. Jones, G.; Barker, A. Reference intervals. *Clin Biochem Rev.* 2008, 29 (Suppl. 1), S93–S97.

30. Geffré, A.; Friedrichs, K.; Harr, K.; Concordet, D.; Trumel, C.; Braun, J.P. Reference values: A review. *Vet. Clin. Pathol.* 2009, 38, 288–298.

31. Humberg, A.; Kammer, J.; Mordmüller, B.; Kremsner, P.G.; Lell, B. Haematological and biochemical reference intervals for infants and children in Gabon. *Trop. Med. Int. Health.* 2011, 16, 343–348.
32. Odutola, A.A.; Afolabi, M.O.; Jafali, J.; Baldeh, I.; Owolabi, O.A.; Owiafe, P.; Bah, G.; Jaiteh, B.; Mohammed, N.I.; Donkor, S.A.; et al. Haematological and biochemical reference values of Gambian infants. *Trop. Med. Int. Health.* **2014**, *19*, 275–283, doi:10.1111/tmi.12245.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).